Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO)
Key takeaways
- Food and Drug Administration has accepted its Biologics License Application for AVT16, an interchangeable biosimilar candidate to Entyvio.
- The regulatory development represents an important step forward for Alvotech as it advances plans to compete in the market for biosimilar versions of the inflammatory bowel disease treatment.
- According to the company, AVT16 is being developed as an interchangeable biosimilar to Entyvio, a biologic medicine widely used to treat inflammatory bowel diseases.
Alvotech shares jump after FDA accepts Entyvio biosimilar application for review (ALVO) Fiona Craig Mon, June 8, 2026 at 5:41 PM GMT+7 1 min read ALVO medical research woman microscope NEW SIZE ©Adobe Stock Images Alvotech (NASDAQ:ALVO) shares climbed 12% in premarket trading on Thursday after the biotechnology company announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for AVT16, an interchangeable biosimilar candidate to Entyvio.
The regulatory development represents an important step forward for Alvotech as it advances plans to compete in the market for biosimilar versions of the inflammatory bowel disease treatment.
According to the company, AVT16 is being developed as an interchangeable biosimilar to Entyvio, a biologic medicine widely used to treat inflammatory bowel diseases.